Investor Relations
TSXV:NRX | OTCQB:NRXBF | FSE: J90
Transforming Regenerative Medicine
Nurexone's mission is to pioneer regenerative medicine targeting nerve and tissue regeneration for recovery from Spinal Cord Injuries (SCI), Traumatic Brain Injury (TBI) and a wide variety of indications.
We're developing ExoPTEN, a first nanodrug aimed at motor, sensory and functional recovery form acute spinal cord injury
Get Investor Updates
Financials & Filings
2024
2023
2022
Latest News
March 14, 2025
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
February 19, 2025
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
February 14, 2025
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
Presentations
Latest
Presentation
One Pager
ISEV TECH
Fact Sheet
AAEV
March 17, 2025
NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery
By Zacks Small Cap Research
FRC provides fee-based coverage
December 11, 2024
Initiating Coverage: A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment
By Fundamental Research Corp.
October 2, 2024
Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries
By Zacks Small Cap Research
Analyst Reports
Events
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
|
23
|
24
|
25
|
26
|
27
|
28
|
1
|
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
|
1
|
2
|
3
|
4
|
5
|
